Decoy Therapeutics Accelerates Path to Clinical Development in Antiviral Innovations Decoy Therapeutics is navigating an active phase, charting its clinical development in antiviral treatments. Key achievements and future plans highlight its rapid momentum.

Decoy Therapeutics Accelerates Path to Clinical Development in Antiviral Innovations #United_States #Cambridge #Decoy_Therapeutics #D-MAVs #IMP³ACT

Decoy Therapeutics Achieves Nasdaq Compliance After Minimum Bid Price Requirement Decoy Therapeutics, Inc. has successfully regained compliance with Nasdaq's Minimum Bid Price Requirement, ensuring its continued listing on the exchange.

Decoy Therapeutics Achieves Nasdaq Compliance After Minimum Bid Price Requirement #USA #NASDAQ #Cambridge,_Massachusetts #Decoy_Therapeutics #Minimum_Bid

Decoy Therapeutics Partners with Quantori to Enhance AI-Driven Peptide Design via Google Cloud Decoy Therapeutics announces a strategic collaboration with Quantori, supported by Google Cloud funding, to significantly improve peptide design speed and efficacy in antiviral research.

Decoy Therapeutics Partners with Quantori to Enhance AI-Driven Peptide Design via Google Cloud #United_States #Cambridge #Google_Cloud #Decoy_Therapeutics #Quantori

Decoy Therapeutics Plans a Reverse Stock Split to Comply with Nasdaq Listing Rule Decoy Therapeutics Inc. announces a 1-for-12 reverse stock split, aiming for compliance with Nasdaq’s minimum bid price requirement.

Decoy Therapeutics Plans a Reverse Stock Split to Comply with Nasdaq Listing Rule #USA #Cambridge #Biopharmaceutical #Decoy_Therapeutics #DCOY

Decoy Therapeutics Enhances Communication with Investors via Webull Corporate Connect Service Decoy Therapeutics has joined the Webull Corporate Connect Service to improve communication and transparency with shareholders, enhancing investor engagement.

Decoy Therapeutics Enhances Communication with Investors via Webull Corporate Connect Service #United_States #Cambridge #Investor_Relations #Webull #Decoy_Therapeutics

Decoy Therapeutics to Showcase Innovations at Webull's Virtual Conference in February 2026 Join Decoy Therapeutics on February 10, 2026, for an enlightening session at Webull's Corporate Connect Webinar Series. Explore their advancements in antiviral therapeutics!

Decoy Therapeutics to Showcase Innovations at Webull's Virtual Conference in February 2026 #USA #biopharmaceuticals #Cambridge #Webull #Decoy_Therapeutics

Decoy Therapeutics Unveils Innovative Global Access Commitment for Peptide-Conjugate Antivirals Decoy Therapeutics engages investors through a virtual segment, presenting its Global Access Commitment Agreement to enhance antiviral accessibility worldwide.

Decoy Therapeutics Unveils Innovative Global Access Commitment for Peptide-Conjugate Antivirals #Decoy_Therapeutics #peptide-conjugate #antiviral

Decoy Therapeutics Develops Scalable Peptide-Conjugate Manufacturing for Global Access Decoy Therapeutics has announced a collaboration with the Gates Foundation to create a scalable manufacturing platform for peptide-conjugate antivirals aimed at improving global access, especially in low-income countries.

Decoy Therapeutics Develops Scalable Peptide-Conjugate Manufacturing for Global Access #USA #Gates_Foundation #Cambridge #Decoy_Therapeutics #IMP3ACT_platform

Salarius Pharmaceuticals Secures $7 Million Through Public Offering to Fund Oncology Research Salarius Pharmaceuticals recently announced a $7 million underwritten public offering aimed at financing its clinical oncology programs and merger with Decoy Therapeutics.

Salarius Pharmaceuticals Secures $7 Million Through Public Offering to Fund Oncology Research #USA #Houston #Clinical_Trials #Salarius_Pharmaceuticals #Decoy_Therapeutics